Efficacy of Omalizumab in Treatment of Therapy-Resistant Atopic Dermatitis and Contact Dermatitis
Abstract
Omalizumab selectively binds to immunoglobulin E antibodies and is approved for treatment of allergic asthma. However, its use in dermatologic diseases is increasing. Here, we report three treatment resistant cases, one with atopic dermatitis the other two with contact dermatitis successfully treated with omalizumab with no side effect.
Keywords
References
- 1. El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol 2016;50:84-96.
- 2. Chia JC, Mydlarski PR. Dermatologic uses of omalizumab. J Dermatolog Treat 2017;28:332-337.
- 3. Peng W, Novak N. Pathogenesis of atopic dermatitis. Clin Exp Allergy 2015;45:566-574.
- 4. Novak N. An update on the role of human dendritic cells in patients with atopic dermatitis. J Allergy Clin Immunol 2012;129:879-886.
- 5. Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol 2014;133:1615-1625.
- 6. Kim DH, Park KY, Kim BJ, et al. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2013;38:496-500.
- 7. Park SY, Choi MR, Na JI, et al. Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 2010;22:349-352.
- 8. Wang HH, Li YC, Huang YC. Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis. J Allergy Clin Immunol 2016;138:1719-1722.
- 9. Zink A, Gensbaur A, Zirbs M, et al. Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol 2016;96:72-76.
- 10. Mowad CM, Anderson B, Scheinman P, et al. Allergic contact dermatitis: Patient management and education. J Am Acad Dermatol 2016;74:1043- 1054.